$25.86 Million in Sales Expected for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) This Quarter

Equities research analysts expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to post sales of $25.86 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Enanta Pharmaceuticals’ earnings, with estimates ranging from $19.61 million to $30.26 million. Enanta Pharmaceuticals reported sales of $31.74 million during the same quarter last year, which indicates a negative year over year growth rate of 18.5%. The firm is scheduled to issue its next quarterly earnings report on Monday, February 14th.

On average, analysts expect that Enanta Pharmaceuticals will report full year sales of $103.16 million for the current year, with estimates ranging from $78.40 million to $128.65 million. For the next financial year, analysts expect that the firm will report sales of $166.98 million, with estimates ranging from $101.41 million to $349.59 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, November 22nd. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.31) by $0.09. Enanta Pharmaceuticals had a negative return on equity of 14.86% and a negative net margin of 86.21%. During the same quarter in the prior year, the business posted ($0.55) earnings per share.

A number of analysts have issued reports on ENTA shares. Royal Bank of Canada decreased their price target on Enanta Pharmaceuticals from $74.00 to $72.00 and set a “sector perform” rating for the company in a report on Friday, November 19th. Roth Capital cut their target price on Enanta Pharmaceuticals from $107.00 to $101.00 and set a “buy” rating on the stock in a research report on Tuesday. JMP Securities lifted their target price on Enanta Pharmaceuticals from $111.00 to $116.00 and gave the stock an “outperform” rating in a research report on Tuesday. Jefferies Financial Group began coverage on Enanta Pharmaceuticals in a research report on Wednesday, October 6th. They set a “buy” rating and a $95.00 target price on the stock. Finally, Oppenheimer lifted their target price on Enanta Pharmaceuticals from $55.00 to $73.00 and gave the stock a “market perform” rating in a research report on Wednesday. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Enanta Pharmaceuticals presently has an average rating of “Hold” and an average target price of $89.56.

In other news, VP Nathalie Adda sold 13,453 shares of the firm’s stock in a transaction on Friday, October 8th. The shares were sold at an average price of $70.09, for a total transaction of $942,920.77. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jay R. Luly sold 4,516 shares of Enanta Pharmaceuticals stock in a transaction dated Wednesday, September 15th. The shares were sold at an average price of $59.06, for a total transaction of $266,714.96. The disclosure for this sale can be found here. Insiders have sold 31,563 shares of company stock worth $2,304,747 in the last quarter. Company insiders own 11.74% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its holdings in Enanta Pharmaceuticals by 1,367.7% during the 2nd quarter. Royal Bank of Canada now owns 1,409 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 1,313 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Enanta Pharmaceuticals by 103.4% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,601 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 814 shares during the last quarter. Eaton Vance Management purchased a new position in shares of Enanta Pharmaceuticals in the 1st quarter worth about $115,000. Cubist Systematic Strategies LLC purchased a new position in shares of Enanta Pharmaceuticals in the 1st quarter worth about $201,000. Finally, Squarepoint Ops LLC purchased a new stake in Enanta Pharmaceuticals during the second quarter valued at about $217,000. Institutional investors and hedge funds own 93.02% of the company’s stock.

Shares of NASDAQ ENTA opened at $86.89 on Monday. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -20.94 and a beta of 0.63. The business has a 50-day moving average of $73.41 and a two-hundred day moving average of $56.76. Enanta Pharmaceuticals has a 1 year low of $40.32 and a 1 year high of $102.00.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.

Featured Story: Stock Portfolio Tracker

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.